Insulinoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 28: Line 28:


*Insulinoma is a rare benign [[pancreatic neuroendocrine tumor]] that arises from B islet cells, which are cells that are normally involved in the production of [[insulin]]. Few insulinomas can also produce other hormones such as [[Serotonin]], [[gastrin]], [[ACTH]], [[glucagon]], and [[somatostatin]] <ref name="AlJadir2015">{{cite journal|last1=AlJadir|first1=Saadi|title=Insulinoma: Literature’s Review (Part 1)|journal=Endocrinology&Metabolism International Journal|volume=2|issue=3|year=2015|issn=24730815|doi=10.15406/emij.2015.02.00025}}</ref>
*Insulinoma is a rare benign [[pancreatic neuroendocrine tumor]] that arises from B islet cells, which are cells that are normally involved in the production of [[insulin]]. Few insulinomas can also produce other hormones such as [[Serotonin]], [[gastrin]], [[ACTH]], [[glucagon]], and [[somatostatin]] <ref name="AlJadir2015">{{cite journal|last1=AlJadir|first1=Saadi|title=Insulinoma: Literature’s Review (Part 1)|journal=Endocrinology&Metabolism International Journal|volume=2|issue=3|year=2015|issn=24730815|doi=10.15406/emij.2015.02.00025}}</ref>
* They are usually small(90%), sporadic(90%), solitary(90%) and benign(90%) tumors. Those associated with the MEN1 syndrome are usually malignant and higher recurrence rate(21% at 10 and 20 years) than in those without [[MEN I]] (5% at 10 and 7% at 20 years). <ref name="pmid1677058">{{cite journal| author=Service FJ, McMahon MM, O'Brien PC, Ballard DJ| title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. | journal=Mayo Clin Proc | year= 1991 | volume= 66 | issue= 7 | pages= 711-9 | pmid=1677058 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1677058  }} </ref>. Although there is a case report of a large(9cm), pedunculated and weighing more than 100g.<ref name="pmid15522939">{{cite journal| author=Mittendorf EA, Liu YC, McHenry CR| title=Giant insulinoma: case report and review of the literature. | journal=J Clin Endocrinol Metab | year= 2005 | volume= 90 | issue= 1 | pages= 575-80 | pmid=15522939 | doi=10.1210/jc.2004-0825 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15522939  }} </ref>
* They are usually small(90%), sporadic(90%), solitary(90%) and benign(90%) tumors. Those associated with the MEN1 syndrome are usually malignant and higher recurrence rate(21% at 10 and 20 years) than in those without [[MEN I]] (5% at 10 and 7% at 20 years). <ref name="pmid1677058">{{cite journal| author=Service FJ, McMahon MM, O'Brien PC, Ballard DJ| title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. | journal=Mayo Clin Proc | year= 1991 | volume= 66 | issue= 7 | pages= 711-9 | pmid=1677058 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1677058  }} </ref>.  
*Almost all insulinomas are present throughout the pancreas and extrapancreatic ones causing hypoglycemia are rare(<2%)<ref name="pmid23430217">{{cite journal |vauthors=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K |title=Diagnosis and management of insulinoma |journal=World J. Gastroenterol. |volume=19 |issue=6 |pages=829–37 |year=2013 |pmid=23430217 |pmc=3574879 |doi=10.3748/wjg.v19.i6.829 |url=}}</ref>


*It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Inhibitors of mTOR(rapamycin) or dual PI3K/mTOR(NVP-BEZ2235)thus have become new drugs for treating insulinoma. An oral mTOR inhibitor, Everolimus, make better glycemic control in people having insulinoma.<ref name="pmid19129539">{{cite journal| author=Kulke MH, Bergsland EK, Yao JC| title=Glycemic control in patients with insulinoma treated with everolimus. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 2 | pages= 195-7 | pmid=19129539 | doi=10.1056/NEJMc0806740 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19129539  }} </ref> The pathway will give more possibilities for medical treatment.<ref name="pmid22711648">{{cite journal| author=Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L et al.| title=Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. | journal=J Surg Oncol | year= 2012 | volume= 106 | issue= 8 | pages= 972-80 | pmid=22711648 | doi=10.1002/jso.23176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711648  }} </ref>  
*It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Inhibitors of mTOR(rapamycin) or dual PI3K/mTOR(NVP-BEZ2235)thus have become new drugs for treating insulinoma. An oral mTOR inhibitor, Everolimus, make better glycemic control in people having insulinoma.<ref name="pmid19129539">{{cite journal| author=Kulke MH, Bergsland EK, Yao JC| title=Glycemic control in patients with insulinoma treated with everolimus. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 2 | pages= 195-7 | pmid=19129539 | doi=10.1056/NEJMc0806740 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19129539  }} </ref> The pathway will give more possibilities for medical treatment.<ref name="pmid22711648">{{cite journal| author=Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L et al.| title=Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. | journal=J Surg Oncol | year= 2012 | volume= 106 | issue= 8 | pages= 972-80 | pmid=22711648 | doi=10.1002/jso.23176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711648  }} </ref>  

Revision as of 16:55, 17 August 2017

Insulinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Insulinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Insulinoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Insulinoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Insulinoma pathophysiology

CDC on Insulinoma pathophysiology

Insulinoma pathophysiology in the news

Blogs on Insulinoma pathophysiology

Directions to Hospitals Treating Insulinoma

Risk calculators and risk factors for Insulinoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]Parminder Dhingra, M.D. [3]

Overview

Insulinoma may occur as part of other genetic syndromes such as multiple endocrine neoplasia type 1 and von Hippel-Lindau syndrome. On microscopic histopathological analysis, solid or gyriform patterns, usually without glands are characteristic findings of insulinoma.

Genetics

Microscopic Pathology

On microscopic histopathological analysis characteristic findings of insulinoma are:

  • Solid or gyriform patterns, usually without glands


Overview

  • The exact pathogenesis of [disease name] is not fully understood.

OR

  • It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
  • [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
  • Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
  • [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
  • The progression to [disease name] usually involves the [molecular pathway].
  • The pathophysiology of [disease/malignancy] depends on the histological subtype.

Pathophysiology

Pathogenesis

  • Insulinoma is a rare benign pancreatic neuroendocrine tumor that arises from B islet cells, which are cells that are normally involved in the production of insulin. Few insulinomas can also produce other hormones such as Serotonin, gastrin, ACTH, glucagon, and somatostatin [2]
  • They are usually small(90%), sporadic(90%), solitary(90%) and benign(90%) tumors. Those associated with the MEN1 syndrome are usually malignant and higher recurrence rate(21% at 10 and 20 years) than in those without MEN I (5% at 10 and 7% at 20 years). [3].
  • It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Inhibitors of mTOR(rapamycin) or dual PI3K/mTOR(NVP-BEZ2235)thus have become new drugs for treating insulinoma. An oral mTOR inhibitor, Everolimus, make better glycemic control in people having insulinoma.[4] The pathway will give more possibilities for medical treatment.[5]


  • The progression to hypoglycemia is actually because of decreased glucose synthesis rather than increased use due to the direct effect of insulin on the liver.[7]

Genetics

  • Insulinoma is transmitted in [mode of genetic transmission] pattern.
  • Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
  • The development of [disease name] is the result of multiple genetic mutations.

Associated Conditions

Gross Pathology

  • On gross pathology insulinomas have a red brown appearance, are usually solitary, can be present anywhere in the pancreas(extrapancreatic are very rare).
Insulinoma- Red brown appearance. By Edward Alabraba et al. - Pancreatic insulinoma co-existing with gastric GIST in the absence of neurofibromatosis-1. World Journal of Surgical Oncology 2009, 7:18doi:10.1186/1477-7819-7-18, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=6686376

Microscopic Pathology

  • On microscopic histopathological analysis, [feature2], and [feature3] are characteristic findings of insulinoma.
  • Histopathology of pancreatic endocrine tumor (insulinoma). H&E stain[8]

    Histopathology of pancreatic endocrine tumor (insulinoma). H&E stain[8]

  • Histopathology of pancreatic endocrine tumor (insulinoma)[8]

    Histopathology of pancreatic endocrine tumor (insulinoma)[8]

  • Histopathology of pancreatic endocrine tumor (insulinoma). Chromogranin A immunostain[8]

    Histopathology of pancreatic endocrine tumor (insulinoma). Chromogranin A immunostain[8]

  • Histopathology of pancreatic endocrine tumor (insulinoma). Insulin immunostain[8]

    Histopathology of pancreatic endocrine tumor (insulinoma). Insulin immunostain[8]

References

  1. ↑ Murray PD, McKenzie DT, Swain SL, Kagnoff MF (1987). "Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression". J Immunol. 139 (8): 2669–74. PMID 3498768.
  2. ↑ AlJadir, Saadi (2015). "Insulinoma: Literature's Review (Part 1)". Endocrinology&Metabolism International Journal. 2 (3). doi:10.15406/emij.2015.02.00025. ISSN 2473-0815.
  3. ↑ 3.0 3.1 Service FJ, McMahon MM, O'Brien PC, Ballard DJ (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clin Proc. 66 (7): 711–9. PMID 1677058.
  4. ↑ Kulke MH, Bergsland EK, Yao JC (2009). "Glycemic control in patients with insulinoma treated with everolimus". N Engl J Med. 360 (2): 195–7. doi:10.1056/NEJMc0806740. PMID 19129539.
  5. ↑ Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L; et al. (2012). "Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis". J Surg Oncol. 106 (8): 972–80. doi:10.1002/jso.23176. PMID 22711648.
  6. ↑ Cao, Yanan; Gao, Zhibo; Li, Lin; Jiang, Xiuli; Shan, Aijing; Cai, Jie; Peng, Ying; Li, Yanli; Jiang, Xiaohua; Huang, Xuanlin; Wang, Jiaqian; Wei, Qing; Qin, Guijun; Zhao, Jiajun; Jin, Xiaolong; Liu, Li; Li, Yingrui; Wang, Weiqing; Wang, Jun; Ning, Guang (2013). "Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1". Nature Communications. 4. doi:10.1038/ncomms3810. ISSN 2041-1723.
  7. ↑ Rizza, R. A.; Haymond, M. W.; Verdonk, C. A.; Mandarino, L. J.; Miles, J. M.; Service, F. J.; Gerich, J. E. (1981). "Pathogenesis of Hypoglycemia in Insulinoma Patients: Suppression of Hepatic Glucose Production by Insulin". Diabetes. 30 (5): 377–381. doi:10.2337/diab.30.5.377. ISSN 0012-1797.
  8. ↑ 8.0 8.1 8.2 8.3 Neuroendocrine tumour of the pancreas. Libre Pathology. http://librepathology.org/wiki/index.php/Neuroendocrine_tumour_of_the_pancreas


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Insulinoma_pathophysiology&oldid=1342708"